Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fedro A. Peccatori,Hatem A. Azim,Roberto Orecchia,Harald J. Hoekstra,Nicholas Pavlidis,V. Kesic,George Pentheroudakis +6 more
Reads0
Chats0
TLDR
The aim of this work is to provide a systematic review and meta-analysis of the literature on canine coronavirus infection and its role in infertility and procreation that has been reported on in previous studies and is concerned with the well-being of newborns.About:
This article is published in Annals of Oncology.The article was published on 2013-10-01 and is currently open access. It has received 598 citations till now.read more
Citations
More filters
Journal ArticleDOI
[Cancer during pregnancy: proposal of a clinical care pathway based on a regional cohort.]
TL;DR: In this paper , the authors carried out an observational, retrospective study from 2013 to 2019 including 48 women (all cancer types) from 2013-2019 in Occitania, Italy and defined an "optimal care pathway" and assessed whether it was respected in the breast cancer subgroup of their cohort.
Journal ArticleDOI
Fertility Counseling and Preservation in Breast Cancer
Tal Sella,Ann H. Partridge +1 more
TL;DR: Fertility counseling and preservation have become an integral part of the multidisciplinary care for breast cancer at diagnosis and throughout survivorship and efforts to further individualize recommendations are necessary.
Journal ArticleDOI
A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature
Fabian De Smedt,Frédérique Dessy,L. Carestia,Pamela Baldin,Frank Aboubakar Nana,Philippe Clapuyt,Véronique Boon,Frédéric Amant,Mina Mhallem Gziri +8 more
TL;DR: In this article , the authors described normal fetal development and no obstetric complications in a patient infected with HIV diagnosed with ALK+ mNSCLC, who became pregnant during treatment with alectinib, a third-generation ALK inhibitor.
References
More filters
Journal ArticleDOI
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Joseph A. Sparano,Joseph A. Sparano,Molin Wang,Silvana Martino,Vicky Jones,Edith A. Perez,Tom Saphner,Antonio C. Wolff,George W. Sledge,William C. Wood,Nancy E. Davidson +10 more
TL;DR: In this paper, the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer was compared.
Journal ArticleDOI
Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation
TL;DR: The combination of low-dose FSH with tamoxifen (TamFSH-IVF) or letrozole (Letrozoles- IVF) results in higher embryo yield compared with Tam-IVf, and the letroZole protocol may be preferred because it results in lower peak E2 levels.
Journal Article
Delayed childbearing: more women are having their first child later in life
T J Matthews,Brady E Hamilton +1 more
TL;DR: The age of the mother plays a strong role in a wide range of birth outcomes (e.g., birthweight, multiple births, and birth defects), so it is critical to track the average age at which women have their first birth.
Journal ArticleDOI
Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study.
TL;DR: The diagnosis of most cancer types during pregnancy or lactation does not increase the risk of cause-specific death, and the "healthy mother effect" for women with a postcancer pregnancy is confirmed.
Journal ArticleDOI
Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study
TL;DR: Ovarian stimulation with gonadotropins and letrozole for the purpose of fertility preservation is unlikely to cause substantially increased recurrence risk, and longer-term follow-up is needed to confirm these findings.
Related Papers (5)
Cancer and fertility preservation: international recommendations from an expert meeting
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Halle C. F. Moore,Joseph M. Unger,Kelly-Anne Phillips,Frances M. Boyle,Frances M. Boyle,Erika Hitre,David L. Porter,Prudence A. Francis,Lori J. Goldstein,Henry L. Gomez,Carlos S. Vallejos,Ann H. Partridge,Shaker R. Dakhil,Agustin A. Garcia,Julie R. Gralow,Janine M. Lombard,John F. Forbes,Silvana Martino,William E. Barlow,Carol J. Fabian,Lori M. Minasian,Frank L. Meyskens,Richard D. Gelber,Gabriel N. Hortobagyi,Kathy S. Albain +24 more